These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 39069462)

  • 21. Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.
    Kovac M; Kostanyan L; Mesaros N; Kuriyakose S; Varman M
    Hum Vaccin Immunother; 2018; 14(8):1977-1986. PubMed ID: 29630439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody persistence to diphtheria toxoid, tetanus toxoid,
    Wanlapakorn N; Sarawanangkoor N; Srimuan D; Thatsanathorn T; Thongmee T; Poovorawan Y
    Hum Vaccin Immunother; 2024 Dec; 20(1):2352909. PubMed ID: 38752802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada.
    Iskedjian M; Walker JH; Hemels ME
    Vaccine; 2004 Oct; 22(31-32):4215-27. PubMed ID: 15474711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic considerations for pertussis booster vaccination in adolescents.
    Hay JW; Ward JI
    Pediatr Infect Dis J; 2005 Jun; 24(6 Suppl):S127-33. PubMed ID: 15931140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of Tdap vaccination of adults aged ≥65 years in the prevention of pertussis in the US: a dynamic model of disease transmission.
    McGarry LJ; Krishnarajah G; Hill G; Masseria C; Skornicki M; Pruttivarasin N; Arondekar B; Roiz J; Pelton SI; Weinstein MC
    PLoS One; 2014; 9(1):e72723. PubMed ID: 24416118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trial.
    Scheifele DW; Halperin SA; Ochnio JJ; Ferguson AC; Skowronski DM
    Pediatr Infect Dis J; 2005 Dec; 24(12):1059-66. PubMed ID: 16371866
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pertussis in adolescents and adults: should we vaccinate?
    Lee GM; Lebaron C; Murphy TV; Lett S; Schauer S; Lieu TA
    Pediatrics; 2005 Jun; 115(6):1675-84. PubMed ID: 15930232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
    Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
    Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
    Zepp F; Habermehl P; Knuf M; Mannhardt-Laakman W; Howe B; Friedland LR
    Vaccine; 2007 Jul; 25(29):5248-52. PubMed ID: 17583395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine compared to standard-dose diphtheria, tetanus, acellular pertussis when used as a pre-school booster in UK children: A 5-year follow-up of a randomised controlled study.
    John T; Voysey M; Yu LM; McCarthy N; Baudin M; Richard P; Fiquet A; Kitchin N; Pollard AJ
    Vaccine; 2015 Aug; 33(36):4579-85. PubMed ID: 26165918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic evaluation of an extended acellular pertussis vaccine program for adolescents in Québec, Canada.
    Iskedjian M; Walker JH; De Serres G; Einarson TR
    Paediatr Drugs; 2005; 7(2):123-36. PubMed ID: 15871632
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-benefit analysis of hospital based postpartum vaccination with combined tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap).
    Ding Y; Yeh SH; Mink CA; Zangwill KM; Allred NJ; Hay JW
    Vaccine; 2013 May; 31(22):2558-64. PubMed ID: 23583811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
    Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
    J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis of pertussis booster vaccination for adolescents in Japan.
    Tanaka M; Okubo R; Hoshi SL; Kondo M
    Vaccine; 2024 Mar; 42(8):2081-2088. PubMed ID: 38418340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults.
    Brandon D; Kimmel M; Kuriyakose SO; Kostanyan L; Mesaros N
    Vaccine; 2018 Oct; 36(42):6325-6333. PubMed ID: 30197282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pregnancy dose Tdap and postpartum cocooning to prevent infant pertussis: a decision analysis.
    Terranella A; Asay GR; Messonnier ML; Clark TA; Liang JL
    Pediatrics; 2013 Jun; 131(6):e1748-56. PubMed ID: 23713104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis.
    Purdy KW; Hay JW; Botteman MF; Ward JI
    Clin Infect Dis; 2004 Jul; 39(1):20-8. PubMed ID: 15206048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults.
    Thierry-Carstensen B; Jordan K; Uhlving HH; Dalby T; Sørensen C; Jensen AM; Heilmann C
    Vaccine; 2012 Aug; 30(37):5464-71. PubMed ID: 22776216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pertussis vaccination in pregnancy in Canada: a cost-utility analysis.
    Abu-Raya B; Coyle D; Bettinger JA; Vaudry W; Halperin SA; Sadarangani M;
    CMAJ Open; 2020; 8(4):E651-E658. PubMed ID: 33077536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two consecutive randomized controlled pertussis booster trials in children initially vaccinated in infancy with an acellular vaccine: The first with a five-component Tdap vaccine to 5-year olds and the second with five- or monocomponent Tdap vaccines at age 14-15 years.
    Carlsson RM; Gustafsson L; Hallander HO; Ljungman M; Olin P; Gothefors L; Nilsson L; Netterlid E
    Vaccine; 2015 Jul; 33(31):3717-25. PubMed ID: 26057135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.